Physician profile
David Flores
NPI 1710943154
$11,059.99
in general payments reported to CMS, 2019-2025
42 companies · $4,179 in 2025
The $4,179 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $187 · 2021: $412 · 2022: $432 · 2023: $1,855 · 2024: $2,407 · 2025: $4,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,138 · Travel and Lodging: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,137.87 |
| Travel and Lodging | $1,303.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,717.07 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Intuitive Surgical, INC. | $1,306.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,265.49 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Gilead Sciences, INC. | $732.08 | 2020-2025 | Biktarvy, Sunlenca |
| Olympus Corporation of The Americas | $465.44 | 2019-2025 | |
| Pulmonx Corporation | $443.92 | 2023-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| United Therapeutics Corporation | $422.14 | 2023-2025 | Tyvaso, Orenitram, Tyvaso |
| Edwards Lifesciences Corporation | $288.02 | 2019-2025 | Sapien 3 Ultra Resilia, Hemosphere |
| Mylan Specialty L.P. | $273.80 | 2019-2024 | Yupelri |
| Inari Medical, INC. | $239.17 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Genentech USA, INC. | $232.68 | 2019-2023 | Xolair |
| Insmed, INC. | $221.46 | 2020-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $208.90 | 2022-2025 | Terlivaz, Acthar |
| Abbvie INC. | $203.95 | 2023-2024 | |
| Allergan, INC. | $176.06 | 2019-2020 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $152.04 | 2024-2025 | Pocket Eeg Device |
| Regeneron Healthcare Solutions, INC. | $146.98 | 2019-2025 | Dupixent |
| Medtronic, INC. | $136.11 | 2025 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.70 | 2023-2025 | Ofev, Jascayd, Stiolto Respimat |
| Galvanize Therapeutics, INC | $121.99 | 2024 | Aliya System |
| Novo Nordisk INC | $121.85 | 2024 | |
| Emd Serono, INC. | $106.62 | 2025 | Serostim |
| Pfizer INC. | $99.45 | 2019-2023 | |
| Viatris Specialty LLC | $94.39 | 2025 | Yupelri |
| Genzyme Corporation | $93.79 | 2023-2024 | |
| Verona Pharma, INC. | $86.33 | 2025 | Ohtuvayre |
| Electromed, INC. | $78.98 | 2022-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $71.48 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Amgen INC. | $63.80 | 2024-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $56.36 | 2019-2023 | Zerbaxa, Dificid |
| Stryker Corporation | $48.56 | 2025 | Flowtriever |
| Avadel Cns Pharmaceuticals, LLC | $47.09 | 2024 | Lumryz |
| Inogen, INC. | $28.07 | 2025 | |
| Getinge USA Sales, LLC | $26.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.53 | 2022 | |
| Lilly USA, LLC | $25.18 | 2025 | Mounjaro |
| Baxter Healthcare | $21.46 | 2025 | Hillrom - Monarch Airway Clearance System |
| Axsome Therapeutics, INC. | $16.26 | 2025 | Sunosi |
| Ani Pharmaceuticals, INC. | $15.76 | 2024 | Purified Cortrophin Gel |
| Philips North America LLC | $15.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.